Oncology Pharma Company Announces Launch of Equity Crowdfunding Campaign

(GROSSE POINTE FARMS, MI) March 20, 2022 – SciTech Development LLC, a specialty pharmaceutical company, is pleased to announce the launch of its crowdfunding campaign on StartEngine. SciTech plans to grow the company, scale-up clinical drug manufacturing, and to commence the company's first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphomas are cancers that begin in the lymphatic system, which is part of the body's germ-fighting immune system.

            SciTech’s patented lead drug candidate ST-001 nanoFenretinide is a combination of the company’s proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. We are also pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).

            Earle Holsapple, President of SciTech Development relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech’s scientific breakthroughs will have a profound impact on patients who are battling cancer.

            Visit https://www.startengine.com/scitechdevelopment to invest in SciTech’s crowdfunding campaign, early investors qualify for time-based bonuses. For company, product, and investor information visit www.SciTechSDP.com. Detailed information regarding SciTech’s science and the company can be found at www.SciTechDevelopment.com.

About SciTech Development

SciTech Development LLC is a specialty pharmaceutical company dedicated to advancing breakthrough cancer treatments. SciTech has developed a powerful, new Drug Delivery Platform (SDP) that will revolutionize how safe and promising, yet challenged drugs, can be delivered to kill cancer. SciTech has developed its first, patented drug candidate ST-001-nanoFenretinide that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. SciTech’s innovations will impact its mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SciTech Development is in the pre-revenue clinical stage of development.

About StartEngine

Founded in 2014, StartEngine is an equity crowdfunding platform that gives all types of investors access to startup investing opportunities. The crowdfunding platform is useful to both founders and startups in search of funding for operational expenses and business expansion. More information regarding StartEngine can be found online at https://www.startengine.com/ 

Investment Inquiries           

For terms of the offering and investment inquiries, visit:

https://www.startengine.com/scitechdevelopment